U.S. IPO Weekly Recap: Biotech, Early-Stage Mining, And Bill Ackman Close Out The April IPO Market

Four IPOs priced in the past week, led by three sizable biotechs, alongside 11 blank-check listings. Two IPOs are scheduled for the coming week, with street research expected on one company and lock-ups set to expire for six companies. The update is primarily a capital-markets calendar note rather than a company-specific catalyst.

Analysis

The tape is telling us risk capital is still available, but it’s being rationed by quality and narrative rather than by broad market conviction. Biotech-led issuance with a sidecar of SPACs usually means the marginal IPO buyer is still willing to fund story assets, yet that flow is fragile: these deals depend heavily on aftermarket stability and a quiet volatility backdrop, not just fundamental improvement. In practice, that creates a short-lived window where the best-performing new issues can trade well for 1-4 weeks before incremental supply and research coverage reset expectations.

The bigger second-order effect is competitive pressure on private-market incumbents. A functioning IPO window gives late-stage startups a credible exit, which can pull forward sponsor monetization and revive valuation benchmarks for pre-IPO peers; that helps VC marks for a quarter or two, but it also increases the probability of a mispriced supply overhang later as insider lockups roll off. For healthcare specifically, fresh biotech prints can temporarily lift the whole sub-asset class, but the group often underperforms on a 3-6 month view if revenue visibility is weak and capital raises become a recurring need.

The main risk is that this is a liquidity-driven rather than conviction-driven reopening. If the broad market sees even a modest volatility spike, the weakest new issues and de-SPACed names will likely gap first because they have the least natural sponsorship and the most limited fundamental support. Conversely, if rates or risk appetite improve, the current calendar can extend quickly into a broader issuance wave, which would be negative for aftermarket performance but positive for bankers and late-stage private holders looking to exit.

Contrarian take: the consensus may be overestimating the durability of the IPO window and underestimating how much of the demand is just index- and event-driven flow. The right expression is not to chase the first prints indiscriminately, but to fade lower-quality recent issuance into strength while staying selectively long the rare companies with recurring revenue and limited secondary supply.

Key Decisions for Investors

• Fade weak recent IPOs into the first post-pricing pop: use a 1-3 week horizon to short or buy puts on names with no near-term revenue visibility and high cash burn; risk/reward improves after the first few sessions when early green-shoots attract retail flow.
• Go long a basket of the highest-quality new issues on first-day/first-week pullbacks only if lockup structure is tight and secondary float is limited; target 10-15% upside over 4-8 weeks versus 5-7% downside if the window cools.
• Pair trade: long larger-cap profitable biotech/healthcare enablers vs short speculative IPO/de-SPAC exposures to capture the quality premium if the issuance window expands; use a 1-3 month horizon around research initiation and lockup expiration.
• Avoid chasing SPAC listings outright; treat them as short-duration trading vehicles and consider selling call spreads into post-listing volatility, because the average move is often driven by flow rather than fundamental repricing.
• Set a watchlist for the six upcoming lockup expirations: if shares trade near highs into the unlock, initiate short exposure 5-10 trading days before expiry, since supply often hits ahead of the actual date.